Oncolys BioPharma Inc. - Product Pipeline Review - 2015
Global Markets Direct’s, ‘Oncolys BioPharma Inc. - Product Pipeline Review - 2015’, provides an overview of the Oncolys BioPharma Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Oncolys BioPharma Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides brief overview of Oncolys BioPharma Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Oncolys BioPharma Inc.’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Oncolys BioPharma Inc.’s pipeline products
Reasons to buy
- Evaluate Oncolys BioPharma Inc.’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Oncolys BioPharma Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Oncolys BioPharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Oncolys BioPharma Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oncolys BioPharma Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Oncolys BioPharma Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Our reports have been used by over 10K customers, including:
Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics Summary The Global Biosimilar market by product is projected to grow at a compound annual growth rate (CAGR) of 45.22%. The market is driven mainly by a...
204 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Dec 2018
The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $48.8 billion by 2027. Biomanufacturing is a widely used term to describe the manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing...
110 pages •
By Infiniti Research Limited
• Dec 2018
About this market Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly,...
The global single-use bioprocessing market is anticipated to reach revenues of approximately $7 billion by 2024, growing at a CAGR of more than 14% during 2018-2024. The growing adoption of disposable equipment and accessories to manufacturing biopharmaceuticals, such as vaccines, monoclonal antibodies, and other biologics will encourage...
111 pages •
By Infiniti Research Limited
• Dec 2018
About this market Patients and physician’s willingness to switch to biosimilars is expected to drive growth in the market. Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients...
PharmSource - Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars - 2018 Edition Summary Biosimilars represent a promising solution to healthcare stakeholders and patients in bringing down the costs of biologics and thus providing some respite for cash-strapped payers. For this...
ASEAN and China Biosimilars Market by Molecule Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibody, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, and Peptide), and Application (Blood Disorder, Oncology Disease, Chronic & Autoimmune Disease, Growth Hormone Deficiency, and Others): Opportunity Analysis and Industry...
Asthma - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2018, provides an overview of the Asthma (Respiratory) pipeline landscape. Asthma is a chronic disease involving the airways in the lungs....